Literature DB >> 7066173

Early kinetics of intravenous propranolol.

T C Fagan, T Walle, U K Walle, E C Conradi, G Harmon, T E Gaffney.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7066173      PMCID： PMC1402040          DOI： 10.1111/j.1365-2125.1982.tb01424.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  12 in total

1.  Altered drug binding due to the use of indwelling heparinized cannulas (heparin lock) for sampling.

Authors:  M Wood; D G Shand; A J Wood
Journal:  Clin Pharmacol Ther       Date:  1979-01       Impact factor: 6.875

2.  Immediate effects of intravenous propranolol on various cardiac arrhythmias.

Authors:  L Schamroth
Journal:  Am J Cardiol       Date:  1966-09       Impact factor: 2.778

3.  Assessment of pharmacokinetic constants from postinfusion blood curves obtained after I.V. infusion.

Authors:  J C Loo; S Riegelman
Journal:  J Pharm Sci       Date:  1970-01       Impact factor: 3.534

4.  The predictable relationship between plasma levels and dose during chronic propranolol therapy.

Authors:  T Walle; E C Conradi; U K Walle; T C Fagan; T E Gaffney
Journal:  Clin Pharmacol Ther       Date:  1978-12       Impact factor: 6.875

5.  Naphthoxylactic acid after single and long-term doses of propranolol.

Authors:  T Walle; E C Conradi; U K Walle; T C Fagan; T E Gaffney
Journal:  Clin Pharmacol Ther       Date:  1979-11       Impact factor: 6.875

6.  Association of in vivo and in vitro propranolol levels in canine Purkinje fibers with antiarrhythmic effects.

Authors:  J K Pruett; T Walle; E E Bagwell
Journal:  J Pharmacol Exp Ther       Date:  1977-07       Impact factor: 4.030

7.  Presystemic and systemic glucuronidation of propranolol.

Authors:  T Walle; T C Fagan; E C Conradi; U K Walle; T E Gaffney
Journal:  Clin Pharmacol Ther       Date:  1979-08       Impact factor: 6.875

Review 8.  Clinical pharmacokinetics of propranolol.

Authors:  P A Routledge; D G Shand
Journal:  Clin Pharmacokinet       Date:  1979 Mar-Apr       Impact factor: 6.447

9.  4-Hydroxypropranolol and its glucuronide after single and long-term doses of propranolol.

Authors:  T Walle; E C Conradi; U K Walle; T C Fagan; T E Gaffney
Journal:  Clin Pharmacol Ther       Date:  1980-01       Impact factor: 6.875

10.  Temporal relationship between cardiac performance and myocardial uptake of dl-propranolol in man.

Authors:  B Hesse; J F Hansen; E Steiness; D Ehlers; J D Andersen
Journal:  Clin Exp Pharmacol Physiol       Date:  1979 May-Jun       Impact factor: 2.557
View more
  2 in total

1.  Development and Evaluation of a Physiologically Based Pharmacokinetic Drug-Disease Model of Propranolol for Suggesting Model Informed Dosing in Liver Cirrhosis Patients.

Authors:  Muhammad Nasir Kalam; Muhammad Fawad Rasool; Faleh Alqahtani; Imran Imran; Asim Ur Rehman; Naveed Ahmed
Journal:  Drug Des Devel Ther       Date:  2021-03-17       Impact factor: 4.162

2.  PKQuest: a general physiologically based pharmacokinetic model. Introduction and application to propranolol.

Authors:  David G Levitt
Journal:  BMC Clin Pharmacol       Date:  2002-08-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.